The RALES Legacy and Finerenone Use on CKD Patients.
作者信息
Moura-Neto José A, Ronco Claudio
机构信息
Department of Internal Medicine, Bahiana School of Medicine and Public Health, Salvador, Bahia, Brazil.
Department of Nephrology Dialysis & Transplantation, International Renal Research Institute, San Bortolo Hospital, Department of Medicine - DIMED, University of Padova, Vicenza, Italy.
出版信息
Clin J Am Soc Nephrol. 2021 Sep;16(9):1432-1434. doi: 10.2215/CJN.02150221. Epub 2021 Aug 6.
Abstract
摘要
相似文献
1
The RALES Legacy and Finerenone Use on CKD Patients.RALES研究的遗产及非奈利酮在慢性肾脏病患者中的应用
Clin J Am Soc Nephrol. 2021 Sep;16(9):1432-1434. doi: 10.2215/CJN.02150221. Epub 2021 Aug 6.
2
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.在糖尿病肾脏疾病试验中减少心血管死亡率和发病率的非奈利酮设计和基线特征。
Am J Nephrol. 2019;50(5):345-356. doi: 10.1159/000503712. Epub 2019 Oct 30.
3
Finerenone: First Approval.非奈利酮：首次获批。
Drugs. 2021 Oct;81(15):1787-1794. doi: 10.1007/s40265-021-01599-7.
4
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.非奈利酮治疗合并或不合并心力衰竭的慢性肾脏病和 2 型糖尿病患者：FIDELIO-DKD 试验的预先设定亚组分析。
Eur J Heart Fail. 2022 Jun;24(6):996-1005. doi: 10.1002/ejhf.2469. Epub 2022 May 19.
5
[Finerenone: a new step on the way to nephroprotection].非奈利酮：肾保护之路上的新进展
Rev Med Suisse. 2022 Aug 24;18(792):1534-1538. doi: 10.53738/REVMED.2022.18.792.1534.
6
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.在糖尿病肾病试验中评估非奈利酮降低肾衰竭和疾病进展风险的设计和基线特征。
Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713. Epub 2019 Oct 25.
7
New insights of cardiovascular and renal protection in diabetic chronic kidney disease with finerenone.非奈利酮对糖尿病慢性肾脏病心血管和肾脏保护的新见解
Cardiovasc Res. 2022 Mar 25;118(5):e36-e37. doi: 10.1093/cvr/cvac024.
8
Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease?非奈利酮——作为一种非甾体类盐皮质激素受体拮抗剂，它在治疗糖尿病慢性肾病方面，我们是否已经成功？
Expert Opin Pharmacother. 2021 Jul;22(10):1253-1256. doi: 10.1080/14656566.2021.1904892. Epub 2021 Mar 25.
9
[Finerenone in patients with chronic kidney disease and type 2 diabetes mellitus].慢性肾脏病合并2型糖尿病患者使用非奈利酮的情况
Internist (Berl). 2021 May;62(5):577-580. doi: 10.1007/s00108-021-01028-7. Epub 2021 Apr 20.
10
Meta-Analysis of the Efficacy and Safety of Finerenone in Diabetic Kidney Disease.Meta 分析：非奈利酮治疗糖尿病肾病的疗效和安全性。
Kidney Blood Press Res. 2022;47(4):219-228. doi: 10.1159/000521908. Epub 2022 Jan 14.
引用本文的文献
1
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease: Clinical Evidence and Potential Adverse Events.糖尿病肾病中的盐皮质激素受体拮抗剂：临床证据与潜在不良事件
Clin Diabetes. 2024 Sep 20;43(1):43-52. doi: 10.2337/cd24-0036. eCollection 2025 Winter.
2
The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis.双重肾素-血管紧张素-醛固酮系统（RAAS）抑制与糖尿病肾病患者急性肾损伤和高钾血症风险之间的关联：一项系统评价和荟萃分析。
Nephrol Dial Transplant. 2023 Oct 31;38(11):2503-2516. doi: 10.1093/ndt/gfad101.
3
Analysis of urine Raman spectra differences from patients with diabetes mellitus and renal pathologies.分析糖尿病及肾脏病变患者尿液的拉曼光谱差异。
PeerJ. 2023 Feb 27;11:e14879. doi: 10.7717/peerj.14879. eCollection 2023.
4
Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.盐皮质激素受体拮抗剂在治疗2型糖尿病相关慢性肾脏病中的进展
Mayo Clin Proc Innov Qual Outcomes. 2022 Oct 15;6(6):536-551. doi: 10.1016/j.mayocpiqo.2022.09.002. eCollection 2022 Dec.
5
Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.非奈利酮治疗慢性肾脏病的疗效与安全性：一项随机临床试验的系统评价和荟萃分析
Front Pharmacol. 2022 Feb 7;13:819327. doi: 10.3389/fphar.2022.819327. eCollection 2022.
6
Mineralocorticoid receptor antagonists for cardioprotection in chronic kidney disease: a step into the future.用于慢性肾脏病心脏保护的盐皮质激素受体拮抗剂：迈向未来的一步。
J Hum Hypertens. 2022 Aug;36(8):695-704. doi: 10.1038/s41371-021-00641-1. Epub 2022 Jan 4.
7
Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD: Understanding and Mitigating the Risks.慢性肾脏病患者使用盐皮质激素受体拮抗剂时的高钾血症：认识并降低风险
Clin J Am Soc Nephrol. 2022 Mar;17(3):455-457. doi: 10.2215/CJN.13541021. Epub 2021 Dec 1.
Zotero 插件